• Amylyx Pharmaceuticals recently reported that 24- and 48-week results from its Phase 2 open-label HELIOS trial of AMX0035 in adults with Wolfram syndrome were published in The Journal of Clinical Investigation, showing improved pancreatic beta cell function, better glycemic control, and a consistent safety profile.
• Because Wolfram syndrome affects only about 3,000 people in the U.S. with no FDA-approved treatments, these peer-reviewed data highlight AMX0035’s potential to address a rare, high-need condition within Amylyx’s broader neurodegeneration pipeline.
• We’ll now examine how these HELIOS results, especially the reported improvements in glycemic control, may influence Amylyx Pharmaceuticals’ existing investment narrative.

AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

Amylyx Pharmaceuticals Investment Narrative Recap

To own Amylyx, you need to believe avexitide can become the first approved therapy for post bariatric hypoglycemia and fund a broader rare-disease portfolio. The HELIOS Wolfram data are encouraging for AMX0035’s scientific story but do not materially change the near term focus on LUCIDITY Phase 3 readout in Q3 2026 or the key risk that avexitide data, payer access, and uptake may not ultimately support the current build out.

The HELIOS publication sits alongside Amylyx’s recent first quarter 2026 results, which showed a net loss of US$41.28 million as the company continues to invest in avexitide, AMX0318, AMX0114, and AMX0035. That spending, backed by a cash runway guided into 2028, underpins upcoming clinical catalysts, but also reinforces that Amylyx remains a pre revenue, loss making business whose path to self funding depends heavily on future trial outcomes and market reception.

Yet alongside this promising science, there is a key risk investors should be aware of if LUCIDITY fails to deliver and Amylyx needs to…

Amylyx Pharmaceuticals’ narrative projects $107.8 million revenue and $23.1 million earnings by 2029. This implies an earnings increase of about $168 million from -$144.7 million today.

Uncover how Amylyx Pharmaceuticals' forecasts yield a $22.20 fair value, a 63% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were expecting revenue of about US$459.0 million and earnings of roughly US$41.4 million by 2029, so if HELIOS strengthens confidence in AMX0035 while your focus is on whether the PBH opportunity really reaches the roughly 160,000 patients highlighted, you can see how views on Amylyx’s future can differ widely and why it may be worth weighing several possible paths from here.

Explore 3 other fair value estimates on Amylyx Pharmaceuticals - why the stock might be worth less than half the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Amylyx Pharmaceuticals research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Amylyx Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amylyx Pharmaceuticals' overall financial health at a glance.

No Opportunity In Amylyx Pharmaceuticals?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.